Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Mark Agius

Neurology Woodland, CA Medical Doctor

NPI 1003897349 CMS profile 272487

515 Fairchild Ct, Woodland, CA 95695

Open in the dashboard

General payments

$254,398

279 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Mark Agius of Woodland, CA is reported in the CMS Open Payments database as having received $254,398 across 279 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $37,008 45
2019 General $217,390 234

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Agius
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Mark Agius were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Mark Agius Neurology median Middle half National median
2019 $217,390 $474 $118–$2,177 $163
2020 $37,008 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Genzyme Corporation $109,923 95 payments
  2. EMD Serono, Inc. $80,706 113 payments
  3. Novartis Pharmaceuticals Corporation $33,933 39 payments
  4. Genentech USA, Inc. $17,496 14 payments
  5. Alexion Pharmaceuticals, Inc. $12,237 17 payments
  6. Biogen, Inc. $102 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $201,113 68 payments
  2. Travel and Lodging $38,527 95 payments
  3. Consulting Fee $8,243 3 payments
  4. Food and Beverage $6,515 113 payments
Products named General payments · program years 2019–2020
  1. AUBAGIO Multiple Sclerosis $72,849 52 payments
  2. Mavenclad Neurology $47,318 77 payments
  3. LEMTRADA $33,552 34 payments
  4. Mavenclad Neurology $33,383 35 payments
  5. OCREVUS $17,496 14 payments
  6. Soliris $12,237 17 payments
  7. GILENYA $11,187 9 payments
  8. MAYZENT $9,876 12 payments
  9. AUBAGIO Neurology $3,522 9 payments
  10. TECFIDERA $102 1 payment
  11. Other $5 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record